Among the handful of drugmakers to advance a successful COVID-19 vaccine in 2020, Moderna—whose mRNA shot Spikevax was also ...

Shares of Moderna, along with other vaccine makers, dropped further this year as lawmakers advanced President Donald Trump's ...

The biopharma reported disappointing fourth-quarter results, missing bottom line estimates amid a steep decline in COVID-19 ...

Barclays downgraded Moderna (NASDAQ: MRNA) to Equal Weight from Overweight in a note Tuesday, citing policy risks, a lack of ...

The vaccine maker posted a loss of $2.91 per share for the quarter, exceeding analysts' estimates of a $2.73 per share loss.

Moderna currently has two marketed vaccines in its portfolio — the COVID-19 vaccine Spikevax and the recently launched respiratory syncytial virus (RSV) vaccine mResvia. Product sales were down ...

Moderna swung to a loss in the last three months of the year after an early launch of its updated Covid-19 vaccine shifted sales out of the fourth quarter.

The quarter saw Moderna begin transitioning its revenue base as COVID-19 vaccine sales tapered due to changing market dynamics. Spikevax sales alone contributed $923 million in the quarter ...

Moderna stock reversed losses on its fourth-quarter report after CEO Stephane Bancel deflected concerns over RFK Jr. Is MRNA ...

Moderna (NASDAQ:MRNA)'s shares fell 4.1% following the earnings release, reflecting investor disappointment with the larger-than-anticipated loss. The company's COVID-19 vaccine, Spikevax ...